PRELIMINARY PROGRAM

XVII NIBIT MEETING

Oncology embraces immunology: the way forward

NIBIT
Translational Science

www.nibit.org

Verona, October 11-13, 2019

Under the auspices of

Aiom
Associazione Italiana di Oncologia Medica

AIRC
FONDAZIONE AIRC
PER LA RICERCA SUL CANCRO

ALLEANZA
CONTRO
IL CANCRO

Fondazione
Grazia Focacci

fondazionemelanoma
ONLUS

Fondazione
Pezcoller

Fondazione IRCCS
Istituto Nazionale dei Tumori

Sistema Socio Sanitario
Regione
Lombardia

SIICA
Società Italiana di Immunologia
Immunologia Clinica e Allergologia

SOCIETA' ITALIANA DI CANCEROLOGIA

UNIVERSITÀ
di VERONA

WO
for
Women for Oncology Italy

Acknowledgments

GOLD

Bristol-Myers Squibb

NOVARTIS

Roche

SILVER

AKOYA BIOSCIENCES

GILEAD

MSD

AstraZeneca

idera

Pfizer Oncology

CODIAK

Incyte

BRONZE

AMGEN

IGEA CLINICAL BIOPHYSICS

IVTech In-vitro technologies

MERCK

astellas

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

Pierre Fabre Oncology
Una Divisione Pierre Fabre Pharma

STANDARD

Assing The research partner

EuroClone serving science through innovation

PerkinElmer For the Better

Werfen

Scientific Committees and Faculty

NIBIT SCIENTIFIC COMMITTEE

Matteo Bellone (Milano, Italy)
Marco Bregni (Milano, Italy)
Vincenzo Bronte (Verona, Italy)
Mario Paolo Colombo (Milano, Italy)
Massimo Di Nicola (Milano, Italy)
Pier Francesco Ferrucci (Milano, Italy)
Paola Nisticò (Roma, Italy)
Antonio Rosato (Padova, Italy)
Vincenzo Russo (Milano, Italy)
Antonio Sica (Milano, Italy)

LOCAL SCIENTIFIC COMMITTEE

Vincenzo Bronte (Verona, Italy)
Stefania Gori (Verona, Italy)
Michele Milella (Verona, Italy)
Aldo Scarpa (Verona, Italy)

FACULTY

Ranjana Advani – Stanford Cancer Institute (Stanford, USA)

Martina Angi – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Claudio Bassi – Verona Pancreas Institute (Verona, Italy)

Matteo Bellone – IRCCS Ospedale San Raffaele (Milano, Italy)

Federica Benvenuti – ICGEB International Centre for Genetic Engineering and Biotechnology (Trieste, Italy)

Christian Blank – Nederlands Kanker Instituut (Amsterdam, Netherlands)

Roberto Bordonaro – Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione GARIBALDI (Catania, Italy)

Marco Bregni
(Milano, Italy)

Vincenzo Bronte – Università degli Studi di Verona (Verona, Italy)

Luigi Buonaguro – Istituto Nazionale per la Cura dei Tumori "Fond. Pascale" (Napoli, Italy)

Marco Cassatella – Università degli Studi di Verona (Verona, Italy)

Triantafyllos Chavakis – Universitätsklinikum Carl Gustav Carus (Dresden, Germany)

Fabio Ciceri – IRCCS Ospedale San Raffaele (Milano, Italy)

Emilia Cocorocchio – Istituto Europeo di Oncologia – IEO (Milano, Italy)

Mario Paolo Colombo – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Ruggero De Maria – Università Cattolica del Sacro Cuore (Roma, Italy)

Sandra Demaria – Weill Cornell Medicine (New York, USA)

Francesca Demichelis – Università degli Studi di Trento (Trento, Italy)

Serena Di Cosimo – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Massimo Di Nicola – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Pier Francesco Ferrucci – Istituto Europeo di Oncologia – IEO (Milano, Italy)

Carl Figdor – Radboud University (Nijmegen, Netherlands)

Gaetano Finocchiaro – Fondazione IRCCS Istituto Neurologico Carlo Besta (Milano, Italy)

Wolf Herman Fridman – Université Paris Descartes (Paris, France)

Enzo Galligioni – Fondazione Pezcoller (Trento, Italy)

Marina Garassino - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Luca Gattinoni – NIH National Cancer Institute (Bethesda, USA)

Stefania Gori – Ospedale Sacro Cuore Don Calabria (Negrar – VR, Italy)

Massimo Guidoboni – Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (Meldola – FC, Italy)

Sophie Lucas – de Duve Institute – UCLouvain (Bruxelles, Belgium)

Nicholas McGranahan – University College London (London, UK)

Ignacio Melero – Clinica Universidad de Navarra (Navarra, Spain)

Michele Milella – Università degli Studi di Verona (Verona, Italy)

Paola Nisticò – IFO Istituto Regina Elena (Roma, Italy)

Jill O'Donnell-Tormey – Cancer Research Institute (New York, USA)

Maria Pia Protti – IRCCS Ospedale San Raffaele (Milano, Italy)

Antonio Rosato – Università degli Studi di Padova (Padova, Italy)

Vincenzo Russo – IRCCS Ospedale San Raffaele (Milano, Italy)

Sriram Sathy – Codiak Biosciences (Cambridge, USA)

Catherine Sautes-Fridman – UPMC Sorbonne Universités (Paris, France)

Aldo Scarpa – Università degli Studi di Verona (Verona, Italy)

Padmanee Sharma – MD Anderson Cancer Centre (Houston, USA)

Antonio Sica – Istituto Clinico Humanitas (Rozzano – MI, Italy)

Gabriella Sozzi – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)

Catia Traversari – MolMed (Milano, Italy)

Jennifer Wargo - MD Anderson Cancer Centre (Houston, USA)

Preliminary program

Friday, October 11

12:30 Registrations and Light Lunch
13:45 Welcome addresses

SESSION 1 - TUMOR MICROENVIRONMENT (NIBIT-SIICA JOINT SESSION)
Chairs: Marco Cassatella & Vincenzo Russo

14:00 **Wolf-Herman Fridman (Paris, France)**
Context dependent impact of B cells on cancer clinical outcome

14:25 **Sophie Lucas (Bruxelles, Belgium)**
Targeting GARP on human Tregs: a novel approach for the immunotherapy of cancer?

14:50 **Triantafyllos Chavakis (Dresden, Germany)**
Innate immune training in tumor immunotherapy

INVITED AND SELECTED ABSTRACT

15:15 **Catherine Sautes-Fridman (Paris, France)**
Tertiary lymphoid structures at the era of cancer immunotherapy

15:30 2 selected abstracts

16:00 **Coffee Break**

SESSION 2 - ANTIGEN PRESENTING CELLS & ACTIVE IMMUNOTHERAPY
Chairs: Paola Nisticò & Massimo Di Nicola

16:30 **Carl Figdor (Nijmegen, Netherlands)**
Synthetic immune systems to outsmart cancer

16:55 **Nicky McGranahan (London, UK)**
The interplay between lung cancer genome evolution and the immune microenvironment

17:20 **Gaetano Finocchiaro (Milano, Italy)**
Dendritic cells, checkpoint inhibitors and the glioblastoma microenvironment

INVITED AND SELECTED ABSTRACTS

17:45 **Federica Benvenuti (Trieste, Italy)**
The tumor microenvironment inhibits DCs efferocytosis by TIM4 and tumor-antigen cross priming

18:00 2 selected abstracts

18:30 **General Assembly of the NIBIT**

19:30 **Welcome Wine, Cheese & Poster Viewing**

SESSION 3 - ADOPTIVE IMMUNOTHERAPY (NIBIT-ACC JOINT SESSION)
Chairs: Ruggero De Maria & Antonio Rosato

09:00 **Fabio Ciceri (Milano, Italy)**
CAR-T cells in hematologic malignancies

09:25 **Catia Traversari (Milano, Italy)**
The CD44V6 CAR for the treatment of hematopoietic and solid cancers

09:50 **Luca Gattinoni (Bethesda, US)**
CD19-specific CAR CD8+ memory stem cells for the treatment of human B-cell malignancies

INVITED AND SELECTED ABSTRACTS

10:15 2 selected abstracts

10:45 **Coffee break**

SESSION 4 - MODULATING IMMUNOTHERAPY IN SOLID TUMORS (NIBIT-SIC JOINT SESSION)
Chairs: Antonio Sica & Gabriella Sozzi

11:00 **Ranjana Advani (Stanford, US)**
The first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab in relapsed/refractory lymphoma

11:25 **Sandra Demaria (New York, US)**
Effects of radiation on tumor antigenicity and adjuvanticity:
from mice to patients and back

11:50 **Marina Garassino (Milano, Italy)**
Combination Therapies in stage III-IV NSCLC

12:15 **Ignacio Melero (Navarra, Spain)**
On evil and virtuous cytokines in cancer immunotherapy

SELECTED ABSTRACT

12:40 1 selected abstract

13:00 **Lunch & Poster Viewing**

SESSION 5 - MODULATING IMMUNOTHERAPY IN MELANOMA AND OTHER IMMUNE SENSITIVE TUMORS
Chairs: Matteo Bellone & Marco Bregni

14:15 **Jennifer Wargo (Houston, US)**
Microbiome in response and resistance to molecularly targeted therapy for melanoma

14:40 **Christian Blank (Amsterdam, Netherlands)**
Neoadjuvant immunotherapy: the pathway to personalized immunotherapy

15:05 **Pier Francesco Ferrucci (Milano, Italy)**
Triplet therapy with antiBRAF/MEK and antiPD1: rationale and clinical outcome

SELECTED ABSTRACTS

15:30 3 selected abstracts

16:15 **Coffee break**

16:40 **Jill O'Donnell-Tormey (New York, US)**
Vision, persistence, impact: a Nonprofits' role in shaping immuno-oncology

PEZCOLLER KEYNOTE LECTURE
Chairman: Mario P. Colombo

17:00 **Enzo Galligioni (Verona, Italy)**
The Pezcoller Foundation

17:10 **Padmanee Sharma (Houston, US)**
From the clinic to the lab: investigating response and resistance mechanisms
to immune checkpoint therapy

18:15 **POSTER VIEWING**

20:00 **Social Dinner – Palazzo Verità Poeta**

SESSION 6 - FOCUS ON PANCREATIC ADENOCARCINOMA AND OTHER IMMUNE RESISTANT TUMORS
Chairs: Vincenzo Bronte & Michele Milella

09:00 **Aldo Scarpa (Verona, Italy)**
A common platform for next generation diagnosis of solid tumors

09:25 **Maria Pia Protti (Milano, Italy)**
Mechanisms of immune deviation in pancreatic adenocarcinoma

09:50 **Francesca Demichelis (Trento, Italy)**
Molecular drivers in castration-resistant prostate cancer

INVITED AND SELECTED ABSTRACTS

10:15 **Claudio Bassi (Verona, Italy)**
Multimodality in pancreatic cancer treatment: are we really going better?

10:30 1 selected abstract

10:45 **Coffee break**

SESSION 7 - CLINICAL AND RESEARCH HIGHLIGHTS AROUND NIBIT (NIBIT-AIOM Joint Session)
Chairs: Mario P. Colombo & Stefania Gori

11:00 **Roberto Bordonaro (Catania, Italy)**
TBD

11:20 **Massimo Guidoboni (Meldola, Italy)**
Dendritic cell vaccines in 2019: new tricks from an old dog?

11:40 **Luigi Buonaguro (Naples, Italy)**
Cancer Vaccine development for liver cancer

12:00 **Serena Di Cosimo (Milano, Italy)**
Immunomodulatory effect of cyclin kinase inhibitors in breast cancer

NEWS FROM THE INDUSTRY (NON CME SESSION)

12:20 **Sriram Sathy (Cambridge, US)**
Developing and engineered exosome therapeutic platform for Immuno-Oncology

12:35 **Emilia Cocorocchio (Milano, Italy)**
Novel approaches in the treatment of locally advanced melanoma

12:50 **Martina Angi (Milano, Italy)**
Novel approaches in the treatment of uveal melanoma

13:05 **NIBIT Awards Nominations**

13.30 **Adjourn**

Call for abstract

All those interested in taking part may submit an abstract in English, following the guidelines included in the template.

Papers could be selected as oral presentation or poster presentation.

DEADLINES FOR ABSTRACT SUBMISSION AND REGISTRATIONS

Abstracts should be submitted to the e-mail address:
alice.trovato@achelois.eu by September 1, 2019
Abstracts submitted by fax will not be accepted

Abstracts will be reviewed by the Scientific Committee and acceptance will be confirmed, together with all details for presenting your work, by **September 15, 2019.**

The presenting author of an accepted project must register by **September 23, 2019.** Registration in mandatory for presenting the poster.

ABSTRACT FORM

To receive the abstract form template please contact the Organizing Secretariat to the e-mail address **alice.trovato@achelois.eu**

COMPETITION AND PRICE

Applicants <40 years of age with an abstract accepted by the Scientific Committee will be considered for the “NIBIT BASIC SCIENCE AWARD” (€ 2.000,00) and for the “NIBIT TRANSLATIONAL SCIENCE AWARD” (€ 2.000,00)

Useful information

CONGRESS VENUE

CAMERA DI COMMERCIO INDUSTRIA ARTIGIANATO AGRICOLTURA VERONA

Corso Porta Nuova, 96 - 37122 Verona

HOW TO BECOME A NIBIT MEMBER

If you wish to **become a member of NIBIT Association**, please visit
http://nibit.org/iscrizioni.php - The rate is € 50,00 / year
If you pay the annual fee before registration, you are entitled to the NIBIT MEMBER Fee rate.

CONGRESS REGISTRATION FEES

NIBIT Member – over 35 years	€ 150,00 VAT included
NIBIT Member – under 35 years	free of charge
PhD Student	free of charge
Resident	free of charge
Student	free of charge
NIBIT Non-Member – over 35 years	€ 230,00 VAT included
NIBIT Non-Member – under 35 years	€ 230,00 VAT included

To register please access the link **http://achelois.onlinecongress.it/NIBITMeeting2019**

SOCIAL DINNER

The Social Dinner will be held on October 12, 2019 at Palazzo Verità-Poeta. The attendance is open to all registered participants to the XVII NIBIT Meeting with the following criteria:
- **€ 30,00 VAT INCLUDED** for NIBIT Members under 35 years, PhD Students, Residents and Students
- **FREE OF CHARGE** for registered NIBIT Member over 35 years and Non-Member.

Please specify if you would like to attend or not while completing the registration procedure.

C.M.E. ACCREDITATION

The Congress was granted **9,1 C.M.E. credits** from the Italian Ministry of Health for the following specialties: **Physicians** specialized in allergology and clinical immunology, pathological anatomy, clinical biochemistry, general surgery, toracic surgery, palliative care, dermatology and venerology, hematology, general practice medicine, internal medicine, oncology, radiotherapy. **Biologists**. **Biomedical laboratory technician**.

ORGANISING SECRETARIAT

ACHELOÍS PROFESSIONAL CONGRESS ORGANISER

Acheloís - Professional Congress Organiser
Via Larga 8 - 20122 Milano
Tel. 02 2643 6227
e-mail: linda.isella@achelois.eu
ACHELOÍS - Professional Congress Organiser